{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:07:47Z","timestamp":1761127667107},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2002,2]]},"DOI":"10.1038\/sj.bjc.6600121","type":"journal-article","created":{"date-parts":[[2002,9,5]],"date-time":"2002-09-05T18:13:52Z","timestamp":1031249632000},"page":"326-330","source":"Crossref","is-referenced-by-count":45,"title":["Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer"],"prefix":"10.1038","volume":"86","author":[{"given":"X Garc\u00eda","family":"del Muro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Marcuello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Gum\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M A","family":"Climent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Carles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M S\u00e1nchez","family":"Parra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J L","family":"Tisaire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Maroto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J R","family":"Germ\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2002,2,11]]},"reference":[{"key":"BF6600121_CR1","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1200\/JCO.1998.16.8.2722","volume":"16","author":"DF Bajorin","year":"1998","unstructured":"Bajorin DF, McCaffrey J, Hilton S, Mazumdar M, Kelly WK, Scher HI, Spicer J, Herr H & Higgins G (1998) Treatment of patients with transitional cell carcinoma of the urothelial tract with ifosfamide, paclitaxel and cisplatin: a phase II trial. J Clin Oncol 16: 2722\u20132727","journal-title":"J Clin Oncol"},{"key":"BF6600121_CR2","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","volume":"17","author":"DF Bajorin","year":"1999","unstructured":"Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G & Boyle MG (1999) Long-term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17: 3173\u20133181","journal-title":"J Clin Oncol"},{"key":"BF6600121_CR3","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1200\/JCO.2000.18.18.3247","volume":"18","author":"J Bellmunt","year":"2000","unstructured":"Bellmunt J, Guillem V, Paz-Ares L, Gonzalez Larriba JL, Carles J, Batiste Alentorn E, Saenz A, L\u00f3pez Brea M, Font A, Nogue M, Bastus R, Climent MA, de la Cruz JJ, Albanell J, Banus JM, Gallardo E, D\u00edaz-Rubio E, Cort\u00e9s-Funes H & Baselga J (2000) Phase I-II study of paclitaxel, cisplatin and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol 18: 3247\u20133255","journal-title":"J Clin Oncol"},{"key":"BF6600121_CR4","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1093\/jnci\/88.15.1078","volume":"88","author":"F Cardenal","year":"1996","unstructured":"Cardenal F, Montes A, Llort G, Segu\u00ed J & Mes\u00eda R (1996) Typhlitis associated with docetaxel treatment. J Natl Cancer Inst 88: 1078\u20131079","journal-title":"J Natl Cancer Inst"},{"key":"BF6600121_CR5","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/bjc.1998.681","volume":"78","author":"R de Wit","year":"1998","unstructured":"de Wit R, Kruit WH, Stoter G, de Boer M, Kerger J & Verweij J (1998) Docetaxel: an active agent in metastatic urothelial cancer, results of a phase ii study in non-chemotherapy-pretreated patients. Br J Cancer 78: 1342\u20131345","journal-title":"Br J Cancer"},{"key":"BF6600121_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0090-4295(98)00150-2","volume":"52","author":"MA Dimopoulos","year":"1998","unstructured":"Dimopoulos MA, Deliveliotis C, Moulopoulos LA, Papadimitriou C, Mitropoulos D, Anagnostopoulos A, Athanassiades P & Dimopoulos C (1998) Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel. Urology 52: 56\u201360","journal-title":"Urology"},{"key":"BF6600121_CR7","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1023\/A:1008379500436","volume":"10","author":"MA Dimopoulos","year":"1999","unstructured":"Dimopoulos MA, Bakoyannis C, Georgoulias V, Papadimitriou C, Moulopoulos LA, Deliveliotis C, Karayannis A, Varkarakis I, Aravantinos G, Zervas A, Pantazopoulos D, Fountzilas G, Bamias A, Kyriakakis Z, Anagnostopoulos A, Giannopoulos A & Kosmidis P (1999) Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 10: 1385\u20131388","journal-title":"Ann Oncol"},{"key":"BF6600121_CR8","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1200\/JCO.2000.18.5.1058","volume":"18","author":"R Dreicer","year":"2000","unstructured":"Dreicer R, Manola J, Roth BJ, Cohen MB, Hatfiels AK & Wilding G (2000) Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J Clin Oncol 18: 1058\u20131061","journal-title":"J Clin Oncol"},{"key":"BF6600121_CR9","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.1999.17.8.2546","volume":"17","author":"PM Dodd","year":"1999","unstructured":"Dodd PM, McCaffrey JA, Herr H, Mazumdar M, Bacik J, Higgins G, Boyle MG, Scher HI & Bajorin DF (1999) Outcome of chemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 17: 2546\u20132552","journal-title":"J Clin Oncol"},{"key":"BF6600121_CR10","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1200\/JCO.2000.18.4.840","volume":"18","author":"PM Dodd","year":"2000","unstructured":"Dodd PM, McCaffrey J, Hilton S, Mazumdar M, Herr H, Kelly WK, Icasiano E, Boyle MG & Bajorin DF (2000) Phase I evaluation of sequential doxorubicin + gemcitabine then ifosfamide + paclitaxel + cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol 18: 840\u2013846","journal-title":"J Clin Oncol"},{"key":"BF6600121_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2307\/2530297","volume":"38","author":"TR Fleming","year":"1982","unstructured":"Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143\u2013151","journal-title":"Biometrics"},{"key":"BF6600121_CR12","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/bjc.1996.605","volume":"74","author":"SD Fossa","year":"1996","unstructured":"Fossa SD, Sternberg C, Scher H, Theodore CH, Mead B, Dearnaley D, Roberts JT & Skovlund E (1996) Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy. Br J Cancer 74: 1655\u20131659","journal-title":"Br J Cancer"},{"key":"BF6600121_CR13","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.2001.19.9.2527","volume":"19","author":"M Hussain","year":"2001","unstructured":"Hussain M, Vaishampayan U, Du W, Redman B & Smith DC (2001) Combination paclitaxel, carboplatin and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 19: 2527\u20132533","journal-title":"J Clin Oncol"},{"key":"BF6600121_CR14","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1200\/JCO.2000.18.9.1921","volume":"18","author":"D Kaufman","year":"2000","unstructured":"Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol S, Oh W & Stadler W (2000) Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18: 1921\u20131927","journal-title":"J Clin Oncol"},{"key":"BF6600121_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00005392-200101000-00017","volume":"165","author":"S Krege","year":"2001","unstructured":"Krege S, Rembrink V, B\u00f6rgermann CH, Otto T & Rubben H (2001) Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase II study. J Urol 165: 67\u201371","journal-title":"J Urol"},{"key":"BF6600121_CR16","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1200\/JCO.1997.15.5.1853","volume":"15","author":"JA McCaffrey","year":"1997","unstructured":"McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI & Bajorin DF (1997) Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15: 1853\u20131857","journal-title":"J Clin Oncol"},{"key":"BF6600121_CR17","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1200\/JCO.1999.17.9.2876","volume":"17","author":"MJ Moore","year":"1999","unstructured":"Moore MJ, Winquist EW, Murray N, Tannock IF, Huan S, Bennett K, Walsh W & Seymour L (1999) Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17: 2876\u20132881","journal-title":"J Clin Oncol"},{"key":"BF6600121_CR18","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1054\/bjoc.2000.1480","volume":"83","author":"C Mulatero","year":"2000","unstructured":"Mulatero C, McClaren BR, Mason M, Oliver RTD & Gallagher CJ (2000) Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin in the treatment of advanced transitional cell carcinoma. Br J Cancer 83: 1612\u20131616","journal-title":"Br J Cancer"},{"key":"BF6600121_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0959-8049(99)00187-2","volume":"36","author":"D Pectasides","year":"2000","unstructured":"Pectasides D, Visvikis A, Aspropotamotis A, Halikia A, Karvounis N, Dimitriadis M & Athanassiou A (2000) Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial. Eur J Cancer 36: 74\u201379","journal-title":"Eur J Cancer"},{"key":"BF6600121_CR20","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1200\/JCO.1997.15.3.1071","volume":"15","author":"LC Pronk","year":"1997","unstructured":"Pronk LC, Schellens JH, Planting AS, van den Bent MJ, Hilkens PH, van der Burg ME, de Boer-Dennert M, Ma J, Blanc C, Harteveld M, Bruno R, Stoter G & Verweij J (1997) Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 15: 750\u2013758","journal-title":"J Clin Oncol"},{"key":"BF6600121_CR21","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1200\/JCO.1998.16.5.1844","volume":"16","author":"BG Redman","year":"1998","unstructured":"Redman BG, Smith DC, Flaherty L, Du W & Hussain M (1998) Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 16: 1844\u20131848","journal-title":"J Clin Oncol"},{"key":"BF6600121_CR22","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1200\/JCO.1997.15.7.2564","volume":"15","author":"SB Saxman","year":"1997","unstructured":"Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, Loehrer PJ & Trump D (1997) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15: 2564\u20132569","journal-title":"J Clin Oncol"},{"key":"BF6600121_CR23","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.1998.16.10.3392","volume":"16","author":"L Sengelov","year":"1998","unstructured":"Sengelov L, Kamby C, Lund B & Engelholm SA (1998) Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. J Clin Oncol 16: 3392\u20133397","journal-title":"J Clin Oncol"},{"key":"BF6600121_CR24","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1200\/JCO.2000.18.13.2537","volume":"18","author":"EJ Small","year":"2000","unstructured":"Small EJ, Lew D, Redman BG, Petrylak DP, Hammond N, Gross HM, Eastham JA & Crawford ED (2000) Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol 18: 2537\u20132544","journal-title":"J Clin Oncol"},{"key":"BF6600121_CR25","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1002\/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7","volume":"64","author":"C Sternberg","year":"1989","unstructured":"Sternberg C, Yagoda A, Scher H, Watson RC, Geller N, Herr H, Morse MJ, Sogani PC, Vaughan ED & Bander N (1989) Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse. Cancer 64: 2448\u20132458","journal-title":"Cancer"},{"key":"BF6600121_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.1998.16.1.255","volume":"16","author":"DJ Vaughn","year":"1998","unstructured":"Vaughn DJ, Malkowicz SB, Zoltick B, Mick R, Ramchandani P, Holroyde C, Armstead B, Fox K & Wein A (1998) Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol 16: 255\u2013260","journal-title":"J Clin Oncol"},{"key":"BF6600121_CR27","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1023\/A:1008331111654","volume":"10","author":"H Von der Maase","year":"1999","unstructured":"Von der Maase H, Andersen L, Crino L, Weinknecht S & Dogliotti L (1999) Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol 10: 1461\u20131465","journal-title":"Ann Oncol"},{"key":"BF6600121_CR28","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"17","author":"H Von der Maase","year":"2000","unstructured":"Von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kebrat P, S\u00e1nchez-Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM & Conte PF (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 17: 3068\u20133077","journal-title":"J Clin Oncol"},{"key":"BF6600121_CR29","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/bjc.1998.501","volume":"78","author":"CC Zielinski","year":"1998","unstructured":"Zielinski CC, Schnack B, Grbovic M, Brodowicz T, Wiltschke C, Steger G, Pfluger H & Marberger M (1998) Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial. Br J Cancer 78: 370\u2013374","journal-title":"Br J Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6600121","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6600121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6600121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:41:00Z","timestamp":1684413660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6600121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["BF6600121"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6600121","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}